Femtech FimmCyte closes wide-ranging agreement with Richter
FimmCyte, a University of Zurich spin‑off, signed a research and option‑to‑license agreement with Gedeon Richter to co‑develop FMC2, a proprietary antibody candidate intended as a disease‑modifying therapy for endometriosis, with pre‑agreed milestone payments, tiered royalties and an exclusive worldwide license exercisable before first‑in‑human studies.
Why it mattersBecause Gedeon Richter holds an option on FMC2, prioritize due diligence and budget allocation before first‑in‑human.